Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
A legfontosabb adatok
- Fázis
- 4. fázis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Azonosító
- NCT07859839
- A regiszteradat frissítve
- 2026. október 8.
- Eredeti leírás
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.A teljes eredeti leírásKevesebb
A Randomized, Open-labelled, Three-Arm Trial of Gabapentin Versus Benzonatate Versus Standard of Care for Chronic Cough in Interstitial Lung Disease
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.
Bevonási feltételek: Established diagnosis of ILD as defined by above; Chronic cough (>= 8 weeks) with NRS ≥ 4/10; On stable treatment for ≥ 8 weeks at screening; No contraindication to Gabapentin or Benzonatate Therapy.
Kizáró feltételek: Long term oxygen therapy (LTOT); Acute respiratory infection or ILD exacerbation leading to hospitalization within past 8 weeks of screening; Gastroesophageal reflux disease; Upper airway cough syndrome; Decompensated Heart Failure (New York Heart Association (NYHA) Class III/IV); Chronic liver disease (Child-Pugh class B or C); Known hypersensitivity to Gabapentin or Benzonatate; Co-morbid bronchial asthma or chronic obstructive pulmonary disease (COPD); Renal Impairment (eGFR < 30ml/min/1.73m2); Exposure to Gabapentin/Benzonatate within past 4 weeks; Pregnant or Lactating women.